Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy).


Journal

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
ISSN: 1532-429X
Titre abrégé: J Cardiovasc Magn Reson
Pays: England
ID NLM: 9815616

Informations de publication

Date de publication:
11 06 2020
Historique:
received: 25 11 2019
accepted: 15 05 2020
entrez: 12 6 2020
pubmed: 12 6 2020
medline: 15 9 2020
Statut: epublish

Résumé

We aimed to evaluate the effect of early intravenous metoprolol treatment, microvascular obstruction (MVO), intramyocardial hemorrhage (IMH) and adverse left ventricular (LV) remodeling on the evolution of infarct and remote zone circumferential strain after acute anterior ST-segment elevation myocardial infarction (STEMI) with feature-tracking cardiovascular magnetic resonance (CMR). A total of 191 patients with acute anterior STEMI enrolled in the METOCARD-CNIC randomized clinical trial were evaluated. LV infarct zone and remote zone circumferential strain were measured with feature-tracking CMR at 1 week and 6 months after STEMI. In the overall population, the infarct zone circumferential strain significantly improved from 1 week to 6 months after STEMI (- 8.6 ± 9.0% to - 14.5 ± 8.0%; P < 0.001), while no changes in the remote zone strain were observed (- 19.5 ± 5.9% to - 19.2 ± 3.9%; P = 0.466). Patients who received early intravenous metoprolol had significantly more preserved infarct zone circumferential strain compared to the controls at 1 week (P = 0.038) and at 6 months (P = 0.033) after STEMI, while no differences in remote zone strain were observed. The infarct zone circumferential strain was significantly impaired in patients with MVO and IMH compared to those without (P < 0.001 at 1 week and 6 months), however it improved between both time points regardless of the presence of MVO or IMH (P < 0.001). In patients who developed adverse LV remodeling (defined as ≥ 20% increase in LV end-diastolic volume) remote zone circumferential strain worsened between 1 week and 6 months after STEMI (P = 0.036), while in the absence of adverse LV remodeling no significant changes in remote zone strain were observed. Regional LV circumferential strain with feature-tracking CMR allowed comprehensive evaluation of the sequelae of an acute STEMI treated with primary percutaneous coronary intervention and demonstrated long-lasting cardioprotective effects of early intravenous metoprolol. ClinicalTrials.gov, NCT01311700. Registered 8 March 2011 - Retrospectively registered.

Sections du résumé

BACKGROUND
We aimed to evaluate the effect of early intravenous metoprolol treatment, microvascular obstruction (MVO), intramyocardial hemorrhage (IMH) and adverse left ventricular (LV) remodeling on the evolution of infarct and remote zone circumferential strain after acute anterior ST-segment elevation myocardial infarction (STEMI) with feature-tracking cardiovascular magnetic resonance (CMR).
METHODS
A total of 191 patients with acute anterior STEMI enrolled in the METOCARD-CNIC randomized clinical trial were evaluated. LV infarct zone and remote zone circumferential strain were measured with feature-tracking CMR at 1 week and 6 months after STEMI.
RESULTS
In the overall population, the infarct zone circumferential strain significantly improved from 1 week to 6 months after STEMI (- 8.6 ± 9.0% to - 14.5 ± 8.0%; P < 0.001), while no changes in the remote zone strain were observed (- 19.5 ± 5.9% to - 19.2 ± 3.9%; P = 0.466). Patients who received early intravenous metoprolol had significantly more preserved infarct zone circumferential strain compared to the controls at 1 week (P = 0.038) and at 6 months (P = 0.033) after STEMI, while no differences in remote zone strain were observed. The infarct zone circumferential strain was significantly impaired in patients with MVO and IMH compared to those without (P < 0.001 at 1 week and 6 months), however it improved between both time points regardless of the presence of MVO or IMH (P < 0.001). In patients who developed adverse LV remodeling (defined as ≥ 20% increase in LV end-diastolic volume) remote zone circumferential strain worsened between 1 week and 6 months after STEMI (P = 0.036), while in the absence of adverse LV remodeling no significant changes in remote zone strain were observed.
CONCLUSIONS
Regional LV circumferential strain with feature-tracking CMR allowed comprehensive evaluation of the sequelae of an acute STEMI treated with primary percutaneous coronary intervention and demonstrated long-lasting cardioprotective effects of early intravenous metoprolol.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT01311700. Registered 8 March 2011 - Retrospectively registered.

Identifiants

pubmed: 32522198
doi: 10.1186/s12968-020-00638-8
pii: 10.1186/s12968-020-00638-8
pmc: PMC7288440
doi:

Substances chimiques

Adrenergic beta-1 Receptor Antagonists 0
Metoprolol GEB06NHM23

Banques de données

ClinicalTrials.gov
['NCT01311700']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Subventions

Organisme : Department of Health
Pays : United Kingdom

Références

Circulation. 2002 Aug 27;106(9):1083-9
pubmed: 12196333
Circulation. 2018 May 1;137(18):1949-1964
pubmed: 29712696
J Am Heart Assoc. 2016 Jul 11;5(7):
pubmed: 27402229
J Am Coll Cardiol. 2014 Jun 10;63(22):2356-62
pubmed: 24694530
JACC Cardiovasc Imaging. 2015 Dec;8(12):1444-1460
pubmed: 26699113
J Am Coll Cardiol. 2014 Sep 23;64(12):1217-26
pubmed: 25236513
Eur Heart J. 2005 Mar;26(6):549-57
pubmed: 15713695
JACC Cardiovasc Imaging. 2018 Oct;11(10):1448-1457
pubmed: 29248649
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004077
pubmed: 27009468
Eur Heart J. 2005 Dec;26(24):2637-43
pubmed: 16183694
Eur Heart J. 2009 Jun;30(12):1440-9
pubmed: 19346229
JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 1):1188-1198
pubmed: 30219400
Eur Radiol. 2013 May;23(5):1210-7
pubmed: 23179525
J Cardiovasc Magn Reson. 2013 Jun 27;15:58
pubmed: 23806080
J Cardiovasc Magn Reson. 2016 Aug 26;18(1):51
pubmed: 27561421
J Cardiovasc Magn Reson. 2013 Jan 18;15:8
pubmed: 23331550
Sci Rep. 2019 Mar 1;9(1):3239
pubmed: 30824793
JACC Cardiovasc Imaging. 2018 Oct;11(10):1433-1444
pubmed: 29454776
Circ Cardiovasc Imaging. 2016 Jun;9(6):
pubmed: 27283007
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
JACC Cardiovasc Imaging. 2008 May;1(3):282-93
pubmed: 19356440
Circulation. 2017 Oct 3;136(14):1288-1300
pubmed: 28687712
Circulation. 1979 Oct;60(4):866-76
pubmed: 476891
Circulation. 2013 Oct 1;128(14):1495-503
pubmed: 24002794
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):587-95
pubmed: 22887690
Am Heart J. 2012 Oct;164(4):473-480.e5
pubmed: 23067904
Circ Cardiovasc Imaging. 2014 Jan;7(1):74-81
pubmed: 24186962
Eur J Radiol. 2019 Mar;112:121-129
pubmed: 30777200
JACC Cardiovasc Imaging. 2018 Mar;11(3):411-419
pubmed: 28624398
J Am Coll Cardiol. 2010 Sep 21;56(13):1056-62
pubmed: 20846606
Radiology. 2013 Jun;267(3):701-8
pubmed: 23382292
J Cardiovasc Magn Reson. 2014 Jan 22;16:10
pubmed: 24450803
J Cardiovasc Magn Reson. 2015 Mar 10;17:25
pubmed: 25890093

Auteurs

Tomaž Podlesnikar (T)

Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.
Department of Cardiac Surgery, University Medical Centre Maribor, Maribor, Slovenia.
Internal Medicine Clinic, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Gonzalo Pizarro (G)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain.
Ruber Juan Bravo Hospital Universidad Europea, Madrid, Spain.

Rodrigo Fernández-Jiménez (R)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain.
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Jose M Montero-Cabezas (JM)

Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.

Nina Greif (N)

Faculty of Medicine University of Maribor, Maribor, Slovenia.

Javier Sánchez-González (J)

Philips Healthcare, Madrid, Spain.

Chiara Bucciarelli-Ducci (C)

Bristol Heart Institute, Bristol NIHR Cardiovascular Research Centre, University of Bristol and University Hospitals Bristol NHS Trust, Bristol, UK.

Nina Ajmone Marsan (NA)

Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.

Zlatko Fras (Z)

Internal Medicine Clinic, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Jeroen J Bax (JJ)

Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.

Valentin Fuster (V)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Borja Ibáñez (B)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain.
IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain.

Victoria Delgado (V)

Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. v.delgado@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH